BPI Contributor

March 1, 2009

5 Min Read



For 2009, TIDES renews its focus on science. The agenda was put together by leaders in oligonucleotide and peptide development and manufacturing. The result is a program with novel, in-depth scientific data in each presentation. The agenda once again includes comprehensive coverage of drug candidates in development; new strategies for formulation and delivery; and the latest in regulatory updates, quality initiatives, process and analytical development, and manufacturing. This allows you the opportunity to benchmark your progress against that of your peers, advance your program, and meet new collaborators.

This is the place to meet key players in oligonucleotide and peptide drug development and manufacturing as well as raw material and equipment supply. At one venue, you can hear from all leading pharmaceutical and biotech companies developing peptide and oligo drugs and diagnostics, and you can consult with all the important suppliers of products and services in the exhibit hall.


Quality Assurance Tutorial: How to Manage QA in a Phase-Appropriate Manner

Current Topics in Oligonucleotide Manufacturing

Bioanalytical Techniques for Characterization of Peptides and Oligos

Managing Analytical Development and Quality Control of Oligonucleotides

Managing Analytical Development and Quality Control of Peptides


Keynote addresses examine technologies and the market landscape to help attendees plan for future industry trends. The featured keynote presentation is “Not Just a Message: Noncoding RNAs in Biology and Medicine” by Nobel Laureate Thomas R. Cech, distinguished professor at the University of Colorado at Boulder, CO.


Audience Interactive Panel Discussion, “Pay Now or Pay Later: Various Strategies” with moderators Patrick Foster (director of process development at Avecia OligoMedicines) and Gary F. Musso, president of Musso and Associates LLC. Panelists include all presenters from the regulatory session as well as René Thürmer, deputy head of the unit of pharmaceutical biotechnology at the Federal Institute for Drugs and Medical Devices of Germany.

Special Strategy Discussion Forums: Each 90-minute discussion session will allow frank discussion in a small group setting. Come with your specific questions. First-come, first-served participation is limited to the first 40 attendees. Topics include the most pressing challenges: annealing, adopting new technologies, regulatory challenges, market landscapes, and more.

What’s New: This year offers a session on new technologies in two tracks, a start-up showcase, break-out discussion sessions, analytical courses divided by molecule type (one course for peptides, one for oligos), and added benefits:


Your TIDES registration also includes access to IBC’s Fifth International Applications of Nucleic Acids Technologies in Molecular Diagnostics: Accelerating Product Development through Cutting-Edge Regulatory, Business and Technology Strategies 19–20 May 2009.

  • Innovation Showcase for latebreaking investment and collaborative opportunities

  • In-depth courses on quality assurance, manufacturing RNA, and bioanalytical techniques

  • Customized courses for peptides and oligos on managing analytical development and quality control.

This is the only forum that focuses on development, manufacturing, business, and regulatory challenges of oligonucleotides, RNA/DNA — and peptide-based therapeutics and diagnostics. All the key players come to TIDES.

Hear case studies on regulatory strategies from Lilly, Avecia OligoMedicines, OncoGenex, Ipsen, Millennium, and Pfizer to help you mitigate economic and regulatory risks. Hear technical and regulatory strategies from Merck, Bristol-Myers, the University of Washington, Regado, Alnylam, and Isis to help you achieve improved characterization and quality control.

Recombinant Antibodies

16–18 June 2009 — Pullman Hotel (Köln, Germany)



Following the enormous success of last year’s event, Informa Life Sciences is proud to announce the return of Recombinant Antibodies. This premier conference assembles global representatives from industry, academia, and commercial organizations to discuss the potential of antibody therapeutics, the latest innovations and developments. Day 1 focuses on advances in antibody engineering. Day 2 builds on that with an exploration of novel applications for antibodies. And on Day 3, the focus shifts to recent advances in clinical developments including inflammatory and infectious diseases and oncology.

What’s New

Variable Domain Engineering: Antibody engineering and IMGT characterization of a variable domain will be described by Marie-Paule Lefranc, founder and director of IMGT in France. An in-depth case study is on offer from Claire Dobson, team leader in display technology at MedImmune in the United Kingdom.

Antibody-Drug Conjugates: All new data on the latest developments in this challenging area will be presented by leading industry experts from Genentech, Wyeth, and ImmunoGen in the United States.

Regulatory Considerations: TRION Pharma will present findings with the first trifunctional bispecific antibody in the EMEA approval process. Hear the regulatory expectations applicable to early development of recombinant antibodies from the legacy of TeGenero (TGN1412) three years on.

Workshops and Symposia

Preconference Symposium, Monday 15 June 2009, “Latest Developments in Antibody Display, Selection, and Screening Techniques”: This multispeaker symposium focuses on the newest techniques used in the early stages of developing an antibody against a target, selecting and affinity-maturing it. A range of techniques for selection will be presented, from the more familiar phage display to the newly developed emulsion-droplets technique for advanced selection. Hear case studies of their successful application in target identification, screening, and optimization.

Evening Seminar, Discussion, and Dinner, Tuesday 16 June 2009, “Business of Antibodies”: In this informal session, delegates will explore and discuss the landscape of commercial opportunity that has been defined by therapeutic antibody products and how it is changing with the emergence of next-generation antibody technologies. With increased demand from big pharmaceutical companies for biotherapeutics and wide-ranging strategies for securing access to such products, particular emphasis will be placed on discussing mergers/acquisitions and licensing trends in the sector.

Postconference Symposium, Friday 19 June 2009, “A–Z of Therapeutic Antibodies”: This workshop will provide delegates with an in-depth overview of processes involved at every stage of drug discovery for therapeutic antibodies, with practical advice from a range of experts from academia, industry, and regulatory agencies. In addition to hearing key speakers present their points-of-view on this topical area, delegates will have the opportunity to discuss the issues and exchange ideas and strategies.


William Mallet, scientist at Genentech (USA)

Christian Klein, department head of discovery oncology at Roche (Germany)

Ruud de Wildt, manager of biopharm R&D at GlaxoSmithKline (UK)

Steve Coats, director of oncology research at MedImmune (USA)

Walter Schubert, head of the molecular pattern recognition research group at the University of Magdeburg (Germany)

Philip Hamann, principal research chemist at Wyeth Research (USA)

David Blakey, chief scientist at AstraZeneca (UK)

Stefan Dübel, director of the department of biotechnology at the Technical University of Braunschweig (Germany)

Agamemnon Epenetos, chairman of Trojantec (UK)

Patrick Chames, main researcher for CNRS-UPR9027 (France)

Alois Lang, chief operating officer of GeNeuro SA (Switzerland)

Register today, quote CQ3383BPI

You May Also Like